Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
HACKETT PATRICK T reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Patrick T. Hackett received a grant of 10,667 shares of common stock as a stock award at a stated price of $0.00 per share. These RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.
Following this grant, Hackett holds 105,839 shares of Outset Medical common stock directly. He also has indirect ownership of 41,666 shares through the Hackett Family Fund and 83,333 shares through the GST Trust as of the transaction date.
OBOYLE KEVIN C reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Kevin C. O’Boyle received an equity award in the form of restricted stock units covering 10,667 shares of common stock. The award was recorded at a price of $0.00 per share as a compensation grant, not a market purchase.
Following this award, O’Boyle directly holds 34,785 shares of Outset Medical common stock. According to the disclosure, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.
Prange Karen reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical director Karen Prange received a new equity award in the form of restricted stock units (RSUs). The grant covers 10,667 shares of common stock at no cash cost, increasing her direct holdings to 29,334 shares after the transaction.
According to the terms, 100% of the shares underlying these RSUs will vest on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. This award is compensation-related, not an open-market stock purchase.
LANG BRENT D. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Brent D. Lang received a grant of 10,667 shares of Common Stock as a stock award at a stated price of $0.0000 per share. These shares represent the underlying restricted stock units.
According to the terms, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following this award, Lang holds 28,518 shares directly and 16,666 shares indirectly through the Lang Family Trust.
GROSSMAN D KEITH reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director D. Keith Grossman reported an equity award and updated holdings. He received a grant of 10,667 shares of Common Stock at $0.00 per share, described in the footnote as shares underlying RSUs that will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following the grant, he holds 24,585 shares directly and 12,845 shares indirectly through the Grossman Fam Trust.
Drexler Karen reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Karen Drexler reported an equity award of common stock as compensation. She received 10,667 shares at a price of $0.00 per share, reflecting a grant rather than an open-market purchase or sale.
According to the filing, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following the grant, Drexler directly holds 21,317 shares of common stock and indirectly holds 2,083 shares through the Drexler Family Trust.
Outset Medical, Inc. Chief Financial Officer Renee Gaeta reported an open‑market sale of 17,672 shares of Common Stock at $4.94 per share. According to the disclosure, this was a required “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of 32,856 RSU-based shares.
The filing notes that the sale does not represent a discretionary trade by the executive. After the transaction, Gaeta directly holds 113,753 shares of Outset Medical Common Stock, indicating she retains a substantial equity stake following the tax‑related sale.
Outset Medical, Inc. reported the results of its Annual Meeting of Stockholders held on June 4, 2026 via virtual audio webcast. As of the April 9, 2026 record date, 18,529,233 shares of common stock were outstanding and entitled to vote, and 13,890,864 shares were represented at the meeting, establishing a quorum.
Stockholders elected Brent D. Lang and Karen Prange as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers. In addition, stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
OM submitted a Form 144 notice concerning Common Stock. The filing shows 32,856 shares tied to the settlement of vested restricted stock units on 06/03/2026, described as equity compensation for services rendered. The broker listed is Morgan Stanley Smith Barney LLC.
Outset Medical, Inc. reported a leadership change as Executive Vice President, R&D, Operations and Service, Marc Nash, has decided to depart the company. His role will end effective June 5, 2026, as he pursues other professional opportunities.
The company stated that Mr. Nash’s departure is not due to any dispute or disagreement with the company or its management, framing this as a voluntary transition rather than a conflict-driven exit.